Interindividual Variability in Drug-induced Cardiotoxicity Risk
University at Buffalo, SUNY
Clinical evidence suggests that patients with leukemia and Down syndrome are at increased risk for drug-induced cardiotoxicity, increasing the need for safer therapeutic options for specific patient populations. Specifically, the anthracyclines, doxorubicin and daunorubicin, used for the chemotherapy of a variety of cancers leads to the development of cardiotoxicity in some patients. Understanding the risk factors associated with drug-induced cardiotoxicity is essential to improve patient therapies.
Javier Blanco, PhD, an associate professor in the Department of Pharmaceutical Sciences at University at Buffalo, The State University of New York, and his team are studying how specific genetic and epigenetic factors contribute to the variable pharmacodynamics of anthracyclines in relevant patient populations. These projects are providing essential data for the design of: 1) less toxic anti-cancer therapies, and 2) strategies for the identification of patients “at risk” for anthracycline-related cardiotoxicity. These studies include work in heart tissue samples from donors with and without Down syndrome to identify determinants for drug-induced cardiotoxicity in cancer patients with Down syndrome.
Dr. Blanco’s research efforts are aimed at improving cancer chemotherapy for pediatric and adult patients. His group’s work is funded by the NIH and their translational research extends to work with colleagues from the Roswell Park Cancer Institute (RPCI), Buffalo General Hospital, and the Children’s Oncology Group (COG) to test whether genetic and epigenetic variants in specific gene networks impact the risk of cardiotoxicity in cancer survivors.